BindingDB logo
myBDB logout

20 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
26819675 26 Potent Small Agonists of Protease Activated Receptor 2.EBI The University of Queensland
27994760 25 PAR2 Modulators Derived from GB88.EBI The University of Queensland
26725028 11 Benzylamide antagonists of protease activated receptor 2 with anti-inflammatory activity.EBI The University of Queensland
26631441 7 Discovery of 2-aryloxy-4-amino-quinazoline derivatives as novel protease-activated receptor 2 (PAR2) antagonists.EBI Yonsei University
26005518 16 Inhibitors of the PAR-2 Signaling Pathway May Treat Pain and Inflammation.EBI Therachem Research Medilab (India)
23895492 49 Toward drugs for protease-activated receptor 2 (PAR2).EBI The University of Queensland
19473027 21 Further studies at neuropeptide s position 5: discovery of novel neuropeptide S receptor antagonists.EBI National Institute of Neuroscienc
18720984 14 Discovery of potent and selective small-molecule PAR-2 agonists.EBI Acadia Pharmaceuticals
21294569 8 Potent agonists of the protease activated receptor 2 (PAR2).EBI University of Arizona
20873792 16 Novel agonists and antagonists for human protease activated receptor 2.EBI The University of Queensland
32551018 24 Discovery of Novel Nonpeptidic PAR2 Ligands.EBI Friedrich-Alexander University Erlangen-N£Rnberg (Fau)
30655958 20 Design and Evaluation of Heterobivalent PAR1-PAR2 Ligands as Antagonists of Calcium Mobilization.EBI Marquette University
29457894 4 Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions.EBI Shanghai Jiao Tong University
17765542 53 A refined agonist pharmacophore for protease activated receptor 2.EBI University of Queensland
29685684 20 Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells.EBI Marquette University
29798827 5 Isoxazole-tethered diarylheptanoid analogs: Discovery of a new drug-like PAR2 antagonist.EBI Advinus Therapeutics